Relation between activated clotting time during angioplasty and abrupt closure.
暂无分享,去创建一个
R. Califf | C. Nelson | R. Harrington | J. Tcheng | W. Hillegass | R. Stack | H. Phillips | C. Narins
[1] R. Califf,et al. Predicting the risk of abrupt vessel closure after angioplasty in an individual patient. , 1994, Journal of the American College of Cardiology.
[2] Epic Investigators,et al. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.
[3] G. Roubin. Interventional Cardiovascular Medicine: Principles and Practice , 1994 .
[4] C. Gaos,et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. , 1994, Journal of the American College of Cardiology.
[5] J. Ferguson,et al. Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty. , 1994, Journal of the American College of Cardiology.
[6] P. Serruys,et al. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. , 1994, American heart journal.
[7] W. Weintraub,et al. Recent changes in the management and outcome of acute closure after percutaneous transluminal coronary angioplasty. , 1993, The American journal of cardiology.
[8] C. Simpfendorfer,et al. Is aggressive heparinization necessary for elective PTCA? , 1993, Catheterization and cardiovascular diagnosis.
[9] E. Topol,et al. Use of A Direct Antithrombin, Hirulog, in Place of Heparin During Coronary Angioplast , 1993, Circulation.
[10] E. Topol,et al. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. , 1992, Journal of the American College of Cardiology.
[11] P. Serruys,et al. Acute Coronary Artery Occlusion During and After Percutaneous Transluminal Coronary Angioplasty: Frequency, Prediction, Clinical Course, Management, and Follow‐up , 1991, Circulation.
[12] D. Faxon,et al. Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. , 1990, Circulation.
[13] D. Bennett,et al. Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty. , 1990, British heart journal.
[14] L. Klein,et al. Adequate heparinization during PTCA: assessment using activated clotting times. , 1989, Catheterization and cardiovascular diagnosis.
[15] F. Harrell,et al. Regression models in clinical studies: determining relationships between predictors and response. , 1988, Journal of the National Cancer Institute.
[16] V. Fuster,et al. Importance of adequate heparin dosage in arterial angioplasty in a porcine model. , 1988, Circulation.
[17] P. Serruys,et al. Coronary angioplasty for unstable angina: immediate and late results in 200 consecutive patients with identification of risk factors for unfavorable early and late outcome. , 1988, Journal of the American College of Cardiology.
[18] L Schwartz,et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. , 1988, The New England journal of medicine.
[19] P. Serruys,et al. Emergency coronary angioplasty in refractory unstable angina. , 1985, The New England journal of medicine.
[20] P. Hattersley. Activated coagulation time of whole blood. , 1966, JAMA.
[21] D. Cox. The Regression Analysis of Binary Sequences , 1958 .